CN Patent

CN121532400A — 补体因子b抑制剂

Assigned to Li Bang Pharmaceutical Hong Kong Co ltd · Expires 2026-02-13 · 0y expired

What this patent protects

本公开涉及能够抑制补体替代途径的化合物，并且特别是涉及因子B的抑制，以及使用这些化合物治疗或预防与补体替代途径活化相关的疾病或病症的方法。

USPTO Abstract

本公开涉及能够抑制补体替代途径的化合物，并且特别是涉及因子B的抑制，以及使用这些化合物治疗或预防与补体替代途径活化相关的疾病或病症的方法。

Drugs covered by this patent

iptacopan-hydrochloride (IPTACOPAN HYDROCHLORIDE)

Patent Metadata

Patent number: CN121532400A
Jurisdiction: CN
Classification: —
Expires: 2026-02-13
Drug substance claim: No
Drug product claim: No
Assignee: Li Bang Pharmaceutical Hong Kong Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.